Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the Phase III SURPASS ET trial (NCT04285086), which is comparing the efficacy of ropeginterferon alfa-2b to anagrelide as second-line therapy in patients with essential thrombocythemia (ET). The primary endpoint of this study is evaluation of the control of hematologic parameters after 12 months of treatment. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть